Hemostatic Anchorage Substrates for Implantable Medical Devices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing anchorage devices do not effectively stop or reduce blood flow at surgical sites and speed up the blood clotting process while securing implantable medical devices to tissue.
Innovation Solution
Anchorage devices incorporating a hemostatic agent, such as tranexamic acid, are integrated into the substrate, which can be woven, knitted, or braided from filaments or fibers, allowing for controlled elution to promote hemostasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anchorage devices are used to secure implantable medical devices to tissue, then anchoring support is provided during healing, but blood flow at the surgical site is not effectively stopped or reduced
Solution Approach 1:
The patent combines two functions into a single device: the anchorage function (securing the implantable medical device) and the hemostatic function (stopping blood flow). The substrate that provides mechanical anchoring is integrated with a hemostatic agent, creating a unified device that simultaneously anchors tissue and controls bleeding, eliminating the need for separate hemostatic interventions.
Solution Approach 2:
The hemostatic agent acts as an intermediary substance that mediates between the surgical site and the blood flow. When incorporated into the substrate, this agent intercepts and neutralizes the harmful blood flow effect by promoting clotting, while allowing the substrate to maintain its anchoring function.
2Reliability
If traditional anchorage devices are used, then tissue anchoring is achieved, but the blood clotting process is not accelerated
Solution Approach 1:
The hemostatic agent is pre-incorporated into the substrate before implantation. This preliminary inclusion ensures that as soon as the device is implanted and contacts blood, the hemostatic action begins immediately without requiring additional steps or time for separate hemostatic interventions, thereby accelerating the overall clotting process.
Solution Approach 2:
The substrate with integrated hemostatic agent provides continuous hemostatic action throughout the healing process. The agent remains active within the substrate structure, continuously promoting clotting at the surgical site rather than providing a single-point intervention, which maintains reliable tissue anchoring while continuously managing blood flow.
3Reliability
If hemostatic agents are added to anchorage devices, then blood clotting is enhanced, but device complexity increases
Solution Approach 1:
Rather than adding a separate hemostatic device or component, the patent merges the hemostatic agent directly into the substrate material itself. This integration approach maintains device simplicity by using a single unified structure that performs both anchoring and hemostatic functions, avoiding the complexity of multiple separate components or assembly steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The integration of a hemostatic agent like tranexamic acid enhances clotting by inhibiting fibrinolysis, effectively reducing bleeding and supporting implantable medical devices during the healing process.
Implementation Method 1
The integration of a hemostatic agent like tranexamic acid enhances clotting by inhibiting fibrinolysis, effectively reducing bleeding
Implementation Method 2
anchorage devices incorporating a hemostatic agent, such as tranexamic acid, are integrated into the substrate, which can be woven, knitted, or braided from filaments or fibers, allowing for controlled elution to promote hemostasis
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate formed from a first material and a second material. At least one of the first and second materials includes a hemostatic agent. Kits, systems and methods are disclosed.